World’s Only Hygienic Digital Urine Test Launched
|
By LabMedica International staff writers Posted on 28 Jan 2019 |

Image: The Urine Testing System has been designed to improve the entire process from receiving the sample and recording results, to analysis in the laboratory (Photo courtesy of Clinical Design).
The world’s only hygienic, easy-to-use and accurate digital point-of-care urine test named Urine Testing System was launched at Arab Health 2019 by Clinical Design (Penryn, Cornwall, UK). The digital point-of-care urine test has been designed to improve the entire process from receiving the sample and recording results, to analysis in the laboratory.
The highly intuitive system features sealed, leak-proof samples, automatically timed readings and the ability to save digital results directly into the patient’s electronic health record. No decanting is required, reducing the risk of contamination and false positive samples being sent to laboratories. Digital readings are also more accurate compared to manual urinalysis as they eliminate variation in subjective analysis and the risk of error during manual recording.
Urine Testing System works seamlessly as a closed integrated system and includes a patented, single-use cap containing reagent pads to test ten parameters: leukocytes, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketone, bilirubin and glucose. Once the patient has collected the urine sample, the healthcare professional simply connects UTS-10 Cap; creating a sealed, leak-proof module. This UTS module is then loaded into the UTS Digital Analyzer and the automatically timed, digital results are shown on the integrated LCD screen or in the UTS Desktop Software if connected to a computer.
The sample can be disposed of in clinical waste or be sent to the laboratory with no need to decant. It is specially designed to fit in standard laboratory racking – and can be purchased with or without boric acid depending on laboratory requirements. The current test takes approximately one to two minutes and risks include spillage of a contaminated sample, as well as human errors during analysis and/or the manual recording into a patient's records.
“We have developed a simple integrated system that increases the efficacy of patient point-of-care urine testing and improves first-time diagnosis. It is the only closed urine testing system available anywhere in the world and we are delighted to be able to showcase it at Arab Health 2019,” said Oliver Blackwell, CEO of Clinical Design.
Related Links:
Clinical Design
The highly intuitive system features sealed, leak-proof samples, automatically timed readings and the ability to save digital results directly into the patient’s electronic health record. No decanting is required, reducing the risk of contamination and false positive samples being sent to laboratories. Digital readings are also more accurate compared to manual urinalysis as they eliminate variation in subjective analysis and the risk of error during manual recording.
Urine Testing System works seamlessly as a closed integrated system and includes a patented, single-use cap containing reagent pads to test ten parameters: leukocytes, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketone, bilirubin and glucose. Once the patient has collected the urine sample, the healthcare professional simply connects UTS-10 Cap; creating a sealed, leak-proof module. This UTS module is then loaded into the UTS Digital Analyzer and the automatically timed, digital results are shown on the integrated LCD screen or in the UTS Desktop Software if connected to a computer.
The sample can be disposed of in clinical waste or be sent to the laboratory with no need to decant. It is specially designed to fit in standard laboratory racking – and can be purchased with or without boric acid depending on laboratory requirements. The current test takes approximately one to two minutes and risks include spillage of a contaminated sample, as well as human errors during analysis and/or the manual recording into a patient's records.
“We have developed a simple integrated system that increases the efficacy of patient point-of-care urine testing and improves first-time diagnosis. It is the only closed urine testing system available anywhere in the world and we are delighted to be able to showcase it at Arab Health 2019,” said Oliver Blackwell, CEO of Clinical Design.
Related Links:
Clinical Design
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
- Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
- Mindray Displays New Generation Benchtop Cellular Analysis Line
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- BioSystems Highlights New iFOB Integral System at MedLab 2019
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more
Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more
Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Cancer screening is intended to reduce mortality, but policy decisions often depend on early indicators that may not fully reflect true survival benefit. The emergence of blood-based tests capable of detecting... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen, a company focused on specialized diagnostics, has announced a strategic collaboration with Oxford Nanopore Technologies, which develops nanopore-based sequencing technology, to validate Werfen’s... Read more









